INDEX
NewBridge Pharmaceuticals breadcrumbs-arrow NewBridge Pharmaceuticals Financial Insights

How Much Did NewBridge Pharmaceuticals Raise?
Funding & Key Investors

NewBridge Pharmaceuticals has solidified its position as a critical conduit for medical innovation within the Middle East and North Africa, recently securing a major strategic investment. This latest capital injection, totaling $12M, underscores the firm's ongoing commitment to addressing the regional healthcare access gap. With a cumulative financial backing of $12M, the company continues to scale its operations, effectively bridging the divide between global pharmaceutical developers and the specific therapeutic needs of the MENA patient population.

The organization has demonstrated a consistent growth trajectory since its inception, leveraging its specialized platform to navigate the complexities of regional regulatory environments and distribution networks. By securing this latest round of financing, NewBridge Pharmaceuticals is well-positioned to accelerate its in-licensing activities and expand its footprint across key therapeutic verticals, including oncology, immunology, and rare diseases.

What is NewBridge Pharmaceuticals?

NewBridge Pharmaceuticals
RetailDrug Stores & PharmaciesManufacturing

Established in 2010, NewBridge Pharmaceuticals operates as a sophisticated commercialization platform dedicated to the in-licensing of innovative therapies. The company serves as a vital intermediary, enabling global pharmaceutical entities to penetrate the MENA market while ensuring that healthcare providers and patients gain access to cutting-edge medical treatments. Their operational model is deeply integrated into the regional healthcare ecosystem, focusing on high-impact areas such as gastroenterology, genomics, and hematology. By managing the entire lifecycle of therapeutic commercialization, NewBridge acts as a strategic partner for international firms seeking to navigate the unique socio-economic and regulatory landscapes of the Middle East.

How much funding has NewBridge Pharmaceuticals raised?

NewBridge Pharmaceuticals has raised a total of $12M across 1 funding round:

2010

Series B

$12M

Series B (2010): $12M with participation from Kuwait Life Sciences Company and Burrill & Co.,

Key Investors in NewBridge Pharmaceuticals

Kuwait Life Sciences Company

Kuwait Life Sciences Company is an integrated healthcare firm that focuses on innovative projects and investments within the MENA region, specializing in venture capital and private equity for life sciences.

Burrill & Co.

Burrill and Co. operates as a comprehensive platform facilitating international trade and wholesale connections, supporting businesses in accessing global markets and supply chains.

What's next for NewBridge Pharmaceuticals?

Looking ahead, the infusion of capital is expected to catalyze the company's strategic expansion into emerging therapeutic segments and bolster its existing distribution infrastructure. As the demand for specialized medical care rises across the MENA region, NewBridge is poised to leverage its established network to introduce more advanced genomic and immunological therapies. The firm's focus remains on enhancing patient outcomes through the systematic acquisition of rights to innovative drugs, ensuring that the regional healthcare sector remains aligned with global advancements in medical science. This strategic positioning suggests a robust outlook for the company as it continues to refine its role as a premier regional commercialization partner.

See full NewBridge Pharmaceuticals company page
See More Financial Insights
No matching results.
Refine your search.

Additional financial insights in the Retail industry

Shoe Station
Apparel & Accessories RetailRetail
Camcor
Ecommerce PlatformsRetail
J Andrew Lange
Home Improvement & Hardware RetailRetailArchitecture, Engineering & DesignConstructionCivil Engineering Construction
GeoSupply
Home Improvement & Hardware RetailRetailBuilding MaterialsManufacturing

Frequently Asked Questions Regarding NewBridge Pharmaceuticals Financial Insights

What are the most recent funding rounds that NewBridge Pharmaceuticals has completed, and what were the funding rounds?
NewBridge Pharmaceuticals has recently completed 1 funding rounds: Series B on Sep 19, 2010. What is the total amount of funding NewBridge Pharmaceuticals has raised to date?
NewBridge Pharmaceuticals has raised a total of $12M in funding to date. How many funding rounds has NewBridge Pharmaceuticals completed?
NewBridge Pharmaceuticals has completed 1 funding rounds. How much funding did NewBridge Pharmaceuticals raise in its most recent funding round?
NewBridge Pharmaceuticals raised $12M in its most recent funding round. Who are the lead investors in NewBridge Pharmaceuticals's latest funding round?
The lead investor in NewBridge Pharmaceuticals's latest funding round was Kuwait Life Sciences Company. To access investor data and explore similar companies, sign up for ZoomInfo. Which was the largest funding round in NewBridge Pharmaceuticals's history?
The largest funding round in NewBridge Pharmaceuticals's history was $12M.
See more information about NewBridge Pharmaceuticals

Test Drive ZoomInfo's Directories

Browse Directories

Most Searched Industries

Construction Law Firms & Legal Services Business Services Finance Manufacturing Agriculture Software Accounting & Accounting Services Retail Healthcare Energy, Utilities & Waste Treatment Telecommunications Transportation Real Estate
People SearchCompany Search